



Patrick Joseph, MD, Medical Director - 345 Oyster Point Blvd  
 South San Francisco, CA 94080 - Tel:(800) 777-0177

Client: 00117  
 Phone: (650) 635-1100


Project: 01358  
 Fax: (650) 635-1111

Patient Initials	DOB	Patient ID	Gender	Monogram Accession # <b>08-137434</b>
Date Collected <b>25-MAY-2008 15:20</b>	Date Received 25-MAY-2008 15:20	Date Reported 01-JUN-2008 15:25	Mode H	Report Status <b>FINAL</b>
Investigator Signe Fransen, 345 Oyster Point Blvd., South San Francisco CA 94080 USA			Specimen ID	
Comments			Current Therapy	



**Patient-specific Results**

Drugs	<b>RAL</b>
IC50 (µM)	>1
Fold Change	>MAX



**ADDITIONAL INFORMATION**

**IC50:** Concentration of drug required to inhibit viral replication by 50%. **Fold Change** =  $\frac{IC50_{patient}}{IC50_{reference}}$

**Biological cutoffs** are currently used for integrase inhibitors. The biological cutoff is defined as the 99th percentile of the distribution of fold change in IC50 values from integrase inhibitor-naïve patients.

PhenoSense HIV Integrase is a proprietary, recombinant virus, single replication cycle assay which uses the integrase coding region (amino acids 1-288) of HIV-1 from a patient blood sample to evaluate integrase inhibitor susceptibility. PhenoSense HIV Integrase is validated for testing specimens with HIV-1 viral loads equal to or above 500 copies/mL and should be interpreted only on such specimens. The results should not be used as the sole criteria for patient management. The results have been disclosed to you from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the persons to whom it pertains, or as permitted by law.